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Abstract
Background: To improve adherence to physical activity (PA), behavioural support in the form of behavioural
change counselling may be necessary. However, limited evidence of the effectiveness of home-based PA combined
with counselling in breast cancer patients exists. The aim of this current randomised controlled trial with a parallel
group design was to evaluate the effectiveness of a home-based PA intervention on PA levels, anthropometric
measures, health-related quality of life (HRQoL), and blood biomarkers in breast cancer survivors.
Methods: Eighty post-adjuvant therapy invasive breast cancer patients (age = 53.6 ± 9.4 years; height = 161.2 ± 6.8 cm;
mass = 68.7 ± 10.5 kg) were randomly allocated to a 6-month home-based PA intervention or usual care. The intervention
group received face-to-face and telephone PA counselling aimed at encouraging the achievement of current
recommended PA guidelines. All patients were evaluated for our primary outcome, PA (International PA Questionnaire)
and secondary outcomes, mass, BMI, body fat %, HRQoL (Functional assessment of Cancer Therapy-Breast), insulin
resistance, triglycerides (TG) and total (TC), high-density lipoprotein (HDL-C) and low-density lipoprotein (LDL-C)
cholesterol were assessed at baseline and at 6-months.
Results: On the basis of linear mixed-model analyses adjusted for baseline values performed on 40 patients in each
group, total, leisure and vigorous PA significantly increased from baseline to post-intervention in the intervention
compared to usual care (between-group differences, 578.5 MET-min∙wk−1, p = .024, 382.2 MET-min∙wk−1, p = .010, and
264.1 MET-min∙wk−1, p = .007, respectively). Both body mass and BMI decreased significantly in the intervention
compared to usual care (between-group differences, −1.6 kg, p = .040, and −.6 kg/m2, p = .020, respectively). Of the
HRQoL variables, FACT-Breast, Trial Outcome Index, functional wellbeing, and breast cancer subscale improved
significantly in the PA group compared to the usual care group (between-group differences, 5.1, p = .024; 5.6, p = .001; 1.9
p = .025; and 2.8, p = .007, respectively). Finally, TC and LDL-C was significantly reduced in the PA group compared to the
usual care group (between-group differences, −.38 mmol∙L−1, p = .001; and −.3 mmol∙L−1, p = .023, respectively).
Conclusions: We found that home-based PA resulted in significant albeit small to moderate improvements in self-
reported PA, mass, BMI, breast cancer specific HRQoL, and TC and LDL-C compared with usual care.
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Background
Worldwide, breast cancer is the most frequently diag-
nosed cancer and the leading cause of cancer death
among females [1]. In the UK, female breast cancer has
the highest incidence rate of all cancers [2], and is pre-
dicted to increase by 44 % up to 2020 [3]. Owing largely
to early detection and improved treatment strategies,
UK breast cancer mortality rates are falling [4], resulting
in the largest prevalence of breast cancer survivors in
the UK ever reported.
Due to the prevalence of treatment-related health
concerns and increased risk of developing metabolic
syndrome, recurrence and cardiovascular disease, breast
cancer survivors may require diagnostic, therapeutic,
supportive or palliative services for many years post-
diagnosis [5–7]. Encouraging breast cancer survivors to
adopt a healthy lifestyle post-treatment may reduce the
healthcare burden resulting from treatment-related se-
quelae and improve survival [8]. In particular, higher
levels of physical activity (PA) may reduce risk of recur-
rence and all-cause and breast cancer-related mortality
[9–12]. However, PA levels are generally low among
breast cancer survivors and many women decrease their
PA following diagnosis [13–15]. Therefore, interventions
are required to improve the post-diagnosis PA levels of
breast cancer survivors.
Randomised controlled trials (RCTs) have found
improvements in PA levels, cardiorespiratory fitness,
HRQoL, fatigue and weight maintenance in breast can-
cer survivors participating in PA interventions compared
with control groups [16–27]. However, most PA RCTs
consist of either entirely or partly facility-based interven-
tions, and therefore, the findings of these trials may not
generalise to patients who have limited access to exercise
facilities because of transportation, time-related and
financial difficulties [22]. In addition, facility-based stud-
ies may lack external validity, or real world application,
which limits the translation of their findings into
practice [28]. To overcome this problem some trials
have provided entirely home-based PA interventions
[17, 18, 20, 22, 24–27]. In addition to mitigating transport,
time-related and financial difficulties, home-based inter-
ventions are also advantageous because they are less
expensive than supervised, facility-based interventions
and do not require participants to attend classes or main-
tain a health club membership to sustain PA [22].
For breast cancer survivors to maintain their PA par-
ticipation during and after the specified intervention
period, it is important that they are given behavioural
change support [19]. However, only three home-based
intervention trials included a specific PA behavioural
change support component, consisting of both face-to-
face counselling and support telephone calls [17, 20, 27].
Although the findings of these home-based PA trials are
promising, they had a number of limitations (small sam-
ple sizes and short intervention duration of 12 weeks,
[17, 20, 27]; postmenopausal women only, [17, 27]) that
limit the generalizability of their results. Therefore, the
aim of this current study was to investigate the effects
of a pragmatic (i.e. designed to test the effectiveness of
an intervention in a broad routine clinical practice,
[29]) 6-month home-based PA intervention with coun-
selling on PA levels, weight maintenance, HRQoL, and
blood biomarkers in breast cancer survivors.
Methods
Participants
Women attending breast cancer clinics between January
2010 and March 2013 at Russells Hall Hospital (Dudley
Group NHS Foundation Trust, UK), were invited to par-
ticipate. Participants were eligible to participate if they
were: 1) females aged 18–72 years, 2) diagnosed with in-
vasive breast cancer (Stage I–III) within two years of en-
rolment, 3) post-surgery and had no surgery planned for
the next six months at least, 4) had fully completed ad-
juvant therapy (radiotherapy and/or chemotherapy) not
including hormonal therapy, 5) no previous malignancy,
6) willing to be randomised 7) and willing to maintain
contact with the investigators over the six months. Ex-
clusion criteria included: 1) inability to participate in PA
because of severe disability (e.g. severe arthritic condi-
tions), 2) psychiatric illness and 3) vulnerable subjects,
such as pregnant women or any other patient where PA
was not approved by their oncologist due to the pres-
ence of one or more contraindications to exercise in
cancer patients [30]. Participants who were physically
active at the time of enrolment were not excluded from
participation. The study was approved by the Black
Country NHS Ethics Committee. All participants pro-
vided written consent prior to data collection.
Randomisation
At a Clinic Trials Unit on a different site, a computer
generated random numbers list was used to allocate all
participants into intervention or usual care groups (con-
cealed from the primary researcher), and allocate 40 %
of participants in each group into a substudy involving
cardiorespiratory fitness assessment (data not reported).
Patients were allocated to intervention and usual care
groups on a 1:1 ratio and were stratified based on adju-
vant chemotherapy. Randomisation occurred after par-
ticipants had completed baseline questionnaires and had
a blood sample taken.
Home-based PA intervention
Following randomisation, patients received an interven-
tion aimed at encouraging the adoption of a more phys-
ically active lifestyle. Participants received a face-to-face
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consultation, followed by a support telephone call at the
end of months one, two and three (i.e. a total of 3 tele-
phone calls). During each of the last two months (4 and
5) patients received a mailed PA reminder leaflets en-
couraging their participation in home-based physical ac-
tivity. The intervention was based on the findings from
previous research [31, 32], which suggested that breast
cancer survivors had strong preferences for the receipt
of face-to-face counselling from exercise professionals
and for moderate-intensity PA at home and/or outdoors.
Face-to-face consultations were conducted by the pri-
mary researcher immediately after initial baseline mea-
surements and were based on the four core motivational
interviewing principles: expressing empathy, developing
discrepancy, rolling with resistance and supporting self-
efficacy [33, 34]. To ensure consistency in intervention
delivery, a semi-structured motivational interviewing-
based intervention protocol was developed to guide inter-
vention delivery. The topics covered in the 30–45 min
consultation were similar to other trials that incorporated
a PA counselling component [17, 20, 22, 27], including:
current PA behaviour, decision balance exercise; benefits
of PA in general and specific to breast cancer survivors;
perceived barriers; prompts to seek social support, goal
setting, types and intensities of PA (e.g. explanation of
light, moderate and vigorous PA with examples specific to
participants, such as, taking a brisk walk so that you are
mildly breathless but can still hold a conversation); safety
advice; and basic lifestyle information (e.g. basic dietary in-
formation, portion size, fat intake, smoking, and hydration
in generally and during activity).
The focus of the follow-up phone calls (end of months
1–3) was to prevent relapse back to inactivity and/or
improve maintenance of PA (accumulate 30 min of
moderate-intensity PA on 3–5 days/week), and covered
topics similar to the face-to-face consultation. Calls
lasted approximately 15–20 min and were guided by
standardised phone call scripts. Participants were en-
couraged to telephone the research team should they
encounter any problems or relapse in their efforts to in-
crease their PA. Therefore, our intervention represented
a pragmatic step down approach (i.e. from in-person ses-
sions to telephone calls to postcard prompts), that could
feasibly be employed by cancer care nurses in routine
clinical practice.
The initial goal of the intervention (months 1–3) was
for participants to progress towards accumulating
30 min of moderate intensity PA on three to five days
per week. During months three to six, the intervention
participants were encouraged to work towards accumu-
lating at least 30 min of moderate-intensity PA on five
to seven days per week in broad agreement with current
public health guidelines [35]. If participants were already
achieving this on trial entry they were, as a minimum,
actively encouraged to maintain their level of PA. Partic-
ipants were encouraged to first focus on the frequency
of their PA and then duration.
Participants were given a PA pack consisting of an in-
formation booklet and a DVD (previously developed by
Breast Cancer Care) that provided further information
of topics such as exercising safety, exercise intensity,
dealing with fatigue and exercising with lymphedema.
Information about local physical activity opportunities
was also provided, including an exercise initiative run in
local parks. During the intervention period, participants
were encouraged, but not required to keep PA diaries to
check against whether they were achieving 150 min of
moderate-vigorous PA over each week. Participants were
advised to refrain from activity if they experienced any
problems relating to the PA intervention (e.g. chest pain
or developed a joint problem). If these circumstances oc-
curred, patients would have been advised to contact the
clinical team, and the clinician of the research team
would have made a clinical decision based on the con-
traindications and precautions to PA for patients with
cancer as to whether the patient refrained from PA tem-
porarily or withdrew from the intervention [30].
Usual care group
Participants randomised to the usual care arm received
standard information regarding PA (i.e. current recom-
mended PA guidelines), as provided to all breast cancer
patients treated at the site. Usual care group participants
were instructed to maintain their current lifestyle. After
completion of the intervention participants in the usual
care group were encouraged to adopt a more physically
active lifestyle and were given the same guidance and
physical activity pack as the intervention group.
Outcomes
After randomisation, all participants’ had their height,
mass and body composition measured and completed a
demographics questionnaire, interview-administered
long form International PA Questionnaire (IPAQ), Func-
tional Assessment of Cancer Therapy-Breast (FACT-B)
questionnaire and blood collection. The primary outcome
of the current study was total PA (MET-min∙wk−1).
Body composition (body fat %) was assessed after a 12-h
water-only fast by bioelectrical impedance analysis (BIA)
using a Tanita BC-418 MA Segmental Body Composition
Analyser, which incorporates eight tactile electrode (Tanita
Corporation, Tokyo, Japan). The specific device has a
standard error of <3 % when standard procedures are
followed [36]. Body mass was also measured via the Tanita
analyser and was recorded to the nearest .1 kg. BMI (kg/
m2) was calculated on the basis of measured height and
mass. Standing height was measured without shoes to the
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nearest .5 cm on a portable stadiometer (Seca 214 Road
Rod, Seca gmbh & co. kg., Hamburg, Germany).
Participants completed the validated IPAQ-long form
questionnaire, which assesses the duration (number of
days × hours/min per day) that an individual has en-
gaged in walking, moderate, and vigorous PA across four
domains (occupational, active transportation, domestic,
and leisure) over the past seven days [37]. PA data were
then used to calculate the metabolic equivalent (MET)-
based IPAQ score by weighting each type of activity by
its MET energy requirement (3.3 × walking duration;
4 ×moderate PA duration; 8 × vigorous PA duration).
Data were summed across activity domains to produce a
weighted estimate of total PA (primary outcome) from
all reported activities per week (MET-min∙wk−1), as well
as subtotal of activity for each of the four domains, as
well as walking, moderate and vigorous PA. The IPAQ
allows individuals to be categorised into those who are
meeting the current recommended PA guidelines (high
and moderate PA categories) and those who are not (low
PA category) [35]. Categorisation is based on the following
algorithm: 1) high: vigorous PA on ≥3 days and accumu-
lating ≥1500 MET-min∙wk−1, or ≥7 days of any PA accu-
mulating ≥3000 MET-min∙wk−1; 2) moderate: vigorous PA
on ≥3 days for ≥20 min/day, or moderate PA/walking
on ≥5 days for ≥30 min/day, or ≥5 days of any combin-
ation of PA accumulating ≥600 MET-min∙wk−1; and 3)
low: any combination of PA accumulating <600 MET-
min∙wk−1. The IPAQ has good reliability (Spearman’s
rho = .8) and moderate concurrent validity (Spearman’s
rho = 0.33) when compared to accelerometer data
(Spearman’s rho = .33) [37].
FACT-B is a 36-item compilation of questions subdi-
vided into four primary HRQoL domains, including phys-
ical well-being (PWB; 7-items), social/family well-being
(SWB; 7-items), emotional wellbeing (EWB; 6-items) and
functional well-being (FWB; 7-items), and a disease spe-
cific domain, the breast cancer subscale (BCS; 9-items)
[38]. The four primary HRQoL domains are combined to
provide a 27-item general HRQoL assessment (FACT-G).
The total FACT-B score is calculated by the sum of
FACT-G and breast cancer subscale scores. The Trial
Outcome Index (TOI), which provides an efficient sum-
mary index of physical/functional outcomes was also cal-
culated as the sum of the PWB, FWB and breast cancer
subscale scores. Possible score ranges were 0–36 for the
BCS, 0–104 for the FACT-G, 0–140 for the FACT-B, and
0–92 for the TOI. Higher scores represent better quality
of life or less severe symptoms. FACT-B has been vali-
dated in the breast cancer setting, with good internal
consistency (alpha coefficient = .9), reliability, patient
acceptability and sensitivity to clinically significant change
[38]. All assessments were made at baseline and within
two weeks of completing the 6-month intervention.
Blood collection and laboratory analysis
Participants were instructed not to exercise for at least
28-h before blood collection. Blood was collected between
9:00 a.m. and 11:00 a.m. on the same day as other assess-
ments after 12-h water-only fast. The Vitros® 5, IFS chem-
istry system (Ortho Clinical Diagnostics Inc., Rochester,
New York, USA) was used to measure all lipid compo-
nents; however, total cholesterol (TC), high-density lipo-
protein (HDL-C), and triglycerides (TG) were measured
using multi-layered slides, whereas measurement of low-
density lipoprotein (LDL-C) required a dual chamber
package. Plasma glucose was measured using the
VITROS® 5.1 FS chemistry system (Johnson and Johnson
Inc., Langhorne, PA, USA) and the same procedure as
with cholesterol (but not LDL-C) was followed. Insulin
was estimated from serum stored at −20 °C. The method
of detection is a solid phase two-site chemi-luminescence
immunometric assay. The Immunolite 2000 insulin was
used on the Immulite 2000 Analyser (Siemens Healthcare
Diagnostics, Deerfield, IL, USA). Homeostasis Model As-
sessment (HOMA) of insulin resistance (IR) was evaluated
from fasting glucose and insulin [39].
Sample size calculation and statistical analysis
Power calculations were based on total PA as the primary
outcome. Using a between-group mean (SD) change in
self-reported PA of 16.5 (25.1) MET-h∙wk−1 found in a
similar trial [20], we estimated that with at least 36 partici-
pants in each group (N = 72), the trial would have 80 %
power at p < 0.05. To allow for 10 % attrition we aimed to
recruit 80 participants (40 in each group). Continuous
variables were expressed as mean ± SD, while categorical
data were presented as number of participants and
percentages.
We used linear mixed-model analysis to examine the
differences in the PA intervention group compared with
the usual care group in changes over time from baseline
to 6-month follow-up for all continuous outcome mea-
sures. Each analysis was adjusted for the baseline value
of the outcome to control for between group baseline
imbalances. Other covariates, including age, BMI (for
non-anthropometric analyses), time since diagnosis
(weeks), and time since treatment completion (weeks),
were adjusted for but did not influence estimates so
were not included. For each analysis, to select the best
model, −2 log likelihood (i.e., maximum likelihood ratio
test/deviance test) was used. Compared to a model with
first-order, auto-regressive covariance structure for the
repeated component (time) and a diagonal error covari-
ance structure for the random effect (group), a model
with unstructured variance for the repeated component
and a compound symmetry for the random effect
provided the best model, in all analyses. We used the
intention-to-treat principle. For participants with
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missing data at post-intervention or follow-up, we
included all available data under the missing-at-random
assumption of the mixed-model analysis.
We performed per-protocol analyses among participants
who completed both baseline and post-intervention
assessments using a contemporary magnitude-based infer-
ences approach [40]. In this approach, mean effects of the
PA intervention and their 90 % confidence limits were es-
timated with a spreadsheet [41] via the unequal-variances
t statistic computed for change scores between baseline
and post-intervention in the two groups and adjusted
for baseline values of each outcome. Each participant’s
change score was expressed as a percentage of baseline
score via analysis of log-transformed values, to reduce
bias arising from non-uniformity of error. For this
approach, effect sizes were calculated by dividing the
log-transformed mean differences between intervention
and usual care groups divided by the pooled log-
transformed baseline SD of outcomes. The spreadsheet
also computed quantitative and qualitative chances that
the true effects were beneficial/positive, trivial, and
harmful/decrease when a value for the smallest mean-
ingful change was entered. A Cohen unit of .2 was
employed as the smallest meaningful change in outcomes.
Where the chance of benefit and harm are both >5 %,
the effect is deemed unclear. Qualitative descriptors
were then assigned to the quantitative percentile scores
as follows: 25–75 % possible, 75–95 % likely, and >99 %
most likely.
Chi-square analysis was planned on IPAQ categorical
data but was not possible because greater than 20 % of
the expected counts were less than five and some of the
expected frequencies were below one. Collapsing the
moderate and low categories into one category did not
remedy this. Therefore, the PA data were presented as
frequencies in those who completed post-intervention
assessments. The FACT-B, FACT-G, TOI, and BCS
HRQoL variables were categorised based on whether
participants experienced a minimum clinically important
(based on performance status and pain anchors) increase
from baseline to post-intervention [42]. Chi-square ana-
lysis was then performed to examine intervention and
usual care groups for differences in the number of par-
ticipants who experienced a minimum clinically import-
ant increase in these variables. In the intention to treat
analysis, standardized effect sizes were calculated for all
outcomes by dividing the adjusted between-group differ-
ence of the post-intervention means by the pooled base-
line standard deviation. According to Cohen [43], effect
sizes <.2 indicate ‘no/trivial difference’, effect sizes of .2
to .5 indicate ‘small differences’, effect sizes of .5 to <.8
indicate ‘moderate differences’, and effect sizes ≥.8 indi-
cate ‘considerable differences’. The level of significance
was set at p < .05.
Results
Flow of participants through the trial and recruitment
Eighty participants were recruited for this trial between
January 2010 and March 2013. Flow of participants
through the study is provided in Fig. 1, including
number of recruited participants and reasons of drop-
ping out.
Participant characteristics at baseline
Table 1 provides the baseline characteristics overall and
by group assignment. Baseline data were collected from
80 breast cancer survivors (age = 53.6 ± 9.4 y; height =
161 ± 6.8 cm; mass = 68.7 ± 10.5 kg). The baseline char-
acteristics of participants in the intervention and usual
care groups were overall similar in most demographic
(Table 1), anthropometric characteristics (Tables 1 and 2)
HRQoL and biomarkers (Table 3), with only a few dissi-
milarities (e.g. usual care group reported more co-
morbidities). Those in the usual care group were more
physically active compared with the intervention group at
baseline (Table 2), which was due mainly to a greater
amount of domestic PA. Regarding IPAQ PA categories
(Table 1), at baseline 15 % (n = 6) more participants were
categorised in the high activity category in the usual care
group compared with the intervention group. No adverse
events were reported during the 6-month intervention
period, although one participant in the usual care group
dropped out due to PA unrelated-sciatica (see Fig. 1).
PA outcomes
When adjusted for baseline levels, the intervention re-
sulted in a significant but small increase in total PA
compared to the usual care group (p < .05; d = .44)
(Table 2). In particular, leisure PA and vigorous PA in-
creased significantly and moderately in the intervention
compared with the usual care group over the interven-
tion period (both p ≤ .01; d ≤ .60). The per-protocol,
magnitude-based inference (adjusted for baseline levels)
analysis revealed the effect of the PA intervention was
likely to have been beneficial (80 % likelihood of a bene-
ficial effect) on moderate PA despite a non-significant
main effect, compared with the usual care (Table 4).
However, the effect of the intervention was possibly
beneficial on all other PA (50 % likelihood of a beneficial
effect), except for a possible negative effect on work-
based and active transport.
Regarding categorical PA data, 88 % (n = 7/8) and
12 % (n = 1/8) of the participants in the intervention
group categorised as low activity at baseline, moved to
the moderate and high activity category post-
intervention, respectively. In the usual care group, 50 %
(n = 2/4) remained in the low activity category while
only one participants each moved from low to moder-
ate and high activity categories, post-intervention.
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Anthropometric outcomes
The intervention group experienced trivial but signifi-
cant decreases in both body mass and BMI from base-
line to post-intervention compared with the usual care
group (both p < .05, d < .02). However, no significant
change in body fat % was observed (Table 2).
HRQoL outcomes
Analyses highlighted a significant but small improve-
ment in FACT-B, TOI, FWB and BCS scores in the PA
group compared with the usual care group over the 6-
month intervention period (p < .05 and d < .50, respect-
ively). No significant differences between PA and usual
care groups were found for any of the other HRQoL var-
iables (Table 3). Magnitude-based inference adjusted
analysis of study completers revealed the effect of the
PA intervention was only possibly to have been beneficial
(80 % likelihood of a beneficial effect) on all HRQoL,
compared with the usual care (Table 5).
Chi-square analysis of the FACT-B, FACT-G, TOI, and
BCS variables revealed significant associations between
intervention and usual care groups and the number of
participants who experienced minimum clinically im-
portant increases in TOI, χ2 (1) = 8.34, p = .004, and
BCS, χ2 (1) = 6.19, p = .013. More than twice as many
participants in the intervention group experienced
minimum clinically important improvements in BSC
and TOI between baseline and post-intervention com-
pared with the usual care group (57 %, n = 21/37 vs.
27 %, n = 9/33; and 65 %, n = 24/37 vs. 30 %, n = 10/33).
No significant associations were found between inter-
vention and usual care groups and the number of partic-
ipants who experienced minimum clinically important
changes in FACT-B, χ2 (1) = 1.67, p = .23, and FACT-G,
χ2 (1) = 0.31, p = .63.
Blood biomarker outcomes
We found significant but small reductions in TC and
LDL-C concentrations in the PA group compared with
the usual care group over the 6-month intervention
period (p < .05 and p < .01, respectively, and d < .05) but
not for any of the other parameters studied (Table 3).
Magnitude-based inference adjusted analysis revealed
the effect of the PA intervention was likely and very
likely to have been beneficial (>75 % likelihood of a
beneficial effect) on TC and LDL-C, respectively, com-
pared with the usual care (Table 5).
Discussion
Breast cancer survivors who received a home-based PA
intervention significantly increased our primary out-
come, self-reported total PA compared with usual care.
Fig. 1 Flow of participants through the trial
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Table 1 Personal characteristics of the participants at baseline (intervention, n = 40; usual care, n = 40)
Participants N (%) overall Participants N (%) intervention Participants N (%) usual care
Mean ± s age (y) 53.6 ± 9.4 52.4 ± 10.3 54.7 ± 8.3
Mean ± s time since diagnosis (weeks) 38.0 ± 20.8 42.2 ± 20.0 34.4 ± 21.1
Mean ± sweeks from end of treatment 10.5 ± 9.0 8.9 ± 7.3 12.0 ± 10.3
Ethnic origin:
o White British 76 (95) 38 (95) 38 (95)
o White Irish 1 (1) 0 (0) 1 (3)
o Other white background 1 (1) 1 (3) 0 (0)
o Black Caribbean 2 (3) 1 (3) 1 (3)
BMI (kg/m2):
o BMI=≥ 30 22 (28) 12 (30) 10 (25)
o BMI = 25–29.9 29 (36) 13 (33) 16 (40)
o BMI = <25 29 (36) 15 (38) 14 (36)
Family history of breast cancer:
o Yes 15 (19) 8 (20) 7 (18)
o No 65 (81) 32 (80) 33 (82)
Smoking:
o Ever 33 (41) 12 (30) 21 (52)
o Never 47 (59) 28 (70) 19 (48)
Alcohol drinkers: 57 (71) 28 (70) 29 (72)
Current or previous co-morbidities:
o Diabetes 3 (4) 2 (5) 1 (3)
o Hypertension 12 (15) 4 (10) 8 (20)
o High cholesterol 6 (8) 3 (8) 3 (8)
o Heart disease 4 (5) 2 (5) 2 (5)
o Vascular disease 2 (3) 1 (3) 1 (3)
o Asthma/chronic bronchitis 9 (11) 3 (8) 6 (15)
o Osteoarthritis 13 (16) 4 (10) 9 (23)
o Rheumatoid arthritis 3 (4) 2 (5) 1 (3)
o Kidney disease 2 (3) 0 (0) 2 (5)
Parity 69 (86) 36 (45) 33 (41)
Breast fed children 45 (56) 23 (58) 22 (55)
Currently menstruating 16 (20) 8 (23) 8 (20)
Oral Contraceptive (OC) use (current/previous) 64 (80) 30 (75) 34 (85)
Mean ± s years OC taken 9.2 ± 7.8 10.0 ± 7.9 8.5 ± 7.7
Previous/current use of HRT 21 (26) 9 (22) 12 (30)
Mean ± s years taking HRT 6.9 ± 4.9 5.9 ± 3.8 7.6 ± 5.5
Marital status:
o Married/in relationship 65 (81) 36 (91) 29 (73)
o Single/divorced/separated/widowed 15 (19) 4 (9) 11 (27)
Highest qualification:
o College degree/diploma and above 30 (40) 15 (38) 10 (27)
Employment status:
o Employed full-time/part-time 41 (53) 21 (53) 21 (53)
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Table 1 Personal characteristics of the participants at baseline (intervention, n = 40; usual care, n = 40) (Continued)
IPAQ physical activity category:
o Low activity 15 (19) 8 (20) 7 (18)
o Moderate activity 55 (69) 30 (75) 25 (63)
o High activity 10 (13) 2 (5) 8 (20)
Key: HRT Hormone Replacement Therapy
Table 2 Effect of physical activity (PA) intervention on PA and anthropometric variables (all PA data reported as MET-min∙wk−1)
Within-group change at follow−up Adjusted between-group change at follow−up
Baseline mean (SD) Follow-up mean (SD) Mean change (95 % CI) Mean change (95 % CI) ES p-value
Total PA
Intervention 1354.74 (1073.44) 1899.01 (985.84) 530.11 (203.35 to 856.86) 578.47 (76.09 to 1080.84) .44 .024
Usual care 1974.60 (1478.57) 1968.19 (1133.87) −49.66 (−532.95 to 433.62) Reference
Work-based PA
Intervention 29.12 (117.59) 52.54 (145.10) 21.06 (−20.97 to 63.09) −45.85 (−128.47 to 36.78) −.10 .273
Usual care 203.85 (643.40) 241.24 (635.99) 66.91 (−17.76 to 151.58) Reference
Active transport PA
Intervention 167.89 (160.67) 222.08 (181.90) 42.36 (−35.42 to 120.15) 23.14 (−88.82 to 135.10) .10 .683
Usual care 223.56 (268.35) 255.16 (253.96) 19.20 (−83.73 to 122.13) Reference
Domestic PA
Intervention 623.60 (627.00) 729.54 (663.90) 93.08 (−177.84 to 364.00) 153.61 (−219.72 to 526.93) .23 .417
Usual care 850.68 (698.20) 793.10 (689.33) −59.33 (−393.63 to 274.97) Reference
Leisure PA
Intervention 478.76 (591.57) 875.42 (789.59) 414.03 (242.22 to 585.84) 382.18 (93.75 to 670.61) .61 .010
Usual care 565.79 (671.65) 652.37 (529.02) 31.57 (−237.19 to 300.32) Reference
Walking PA
Intervention 439.64 (416.43) 706.56 (789.59) 289.24 (105.74 to 472.74) 172.93 (−61.75 to 407.61) .39 .147
Usual care 567.16 (472.40) 688.77 (528.71) 116.30 (−59.49 to 289.09) Reference
Moderate PA
Intervention 695.10 (673.94) 856.24 (675.64) 142.49 (−126.52 to 411.49) 112.44 (−307.39 to 532.27) .13 .597
Usual care 1087.60 (1020.28) 1126.04 (911.75) 30.61 (−376.54 to 437.77) Reference
Vigorous PA
Intervention 142.03 (387.19) 275.65 (572.14) 122.11 (17.10 to 227.11) 264.07 (73.51 to 454.64) .59 .007
Usual care 60.60 (143.22) 60.61 (143.22) −143.06 (−340.84 to 54.72) Reference
Mass (kg)
Intervention 70.86 (11.83) 69.43 (12.46) −1.61 (−2.80 to−.42) −1.62 (−3.16 to−.07) −.14 .040
Usual care 69.15 (11.20) 69.19 (12.36) −.00 (−1.03 to 1.04) Reference
BMI (kg/m2)
Intervention 27.25 (4.69) 26.58 (4.93) −.62 (−1.08 to −.17) −.62 (−1.17 to −.06) −.14 .030
Usual care 26.67 (4.04) 26.79 (4.2) −.01 (−.41 to .40) Reference
Body fat %
Intervention 35.88 (6.46) 36.24 (6.61) .41 (−.55 to 1.37) .34 (−.93 to 1.62) .06 .594
Usual care 35.26 (5.90) 35.52 (6.26) .05 (−.85 to .95) Reference
Key: SD indicates standard deviation; 95 % CI, 95 % confidence interval; ES, effect size (Cohen’s d; effect estimate/pooled baseline SD)
Baseline means (SD) are based on 80 participants (intervention = 40; usual care = 40); post-interventions and within-group change at follow-up means (SD) are
based on 70 participants (intervention = 37; control = 33)
Except for the anthropometric measures, positive ES indicate effects in favour of the exercise intervention group
Between-group effects were assessed using linear mixed model analysis, adjusted for the value of the outcome variable at baseline
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Table 3 Effect of PA intervention on HRQoL FACT-B and blood biomarker variables
Within-group change at
follow−up
Adjusted between-group change
at follow−up
Baseline mean (SD) Follow-up mean (SD) Mean change (95 % CI) Mean change (95 % CI) ES p-value
FACT-B
Intervention 108.56 (21.97) 114.41 (21.48) 5.91 (1.88 to 9.93) 5.05 (.69 to 9.40) .25 .024
Usual care 114.25 (18.97) 115.34 (17.57) .56 (−3.43 to 4.56) Reference
FACT-G
Intervention 85.75 (17.35) 88.03 (18.53) 2.62 (−2.72 to 7.96) 2.17 (−1.43 to 5.78) .14 .234
Usual care 89.30 (13.23) 89.59 (16.84) −.09 (−5.65 to 5.46) Reference
TOI
Intervention 65.29 (15.09) 72.59 (15.13) 7.20 (4.47 to 9.93) 5.64 (2.33 to 8.95) .39 .001
Usual care 71.13 (13.07) 73.25 (16.52) 2.13 (−1.89 to 6.14) Reference
PWB
Intervention 22.03 (5.25) 25.54 (9.32) 3.43 (.58 to 6.29) .63 (−.87 to 2.13) .13 .404
Usual care 23.03 (4.39) 25.84 (9.18) 2.84 (−.15 to 5.84) Reference
SWB
Intervention 24.35 (4.44) 23.70 (5.03) −.54 (−1.40 to .32) −.73 (−2.03 to .59) .17 .276
Usual care 23.40 (4.19) 24.13 (4.13) .19 (−1.00 to 1.37) Reference
EWB
Intervention 18.93 (4.61) 20.11 (4.14) 1.24 (.46 to 2.03) .20 (−.85 to 1.26) .05 .701
Usual care 19.73 (3.74) 20.72 (3.30) 1.00 (.20 to 1.80) Reference
FWB
Intervention 20.45 (6.10) 21.95 (4.41) 1.76 (.21 to 3.30) 1.90 (.24 to 3.55) .36 .025
Usual care 23.15 (3.94) 22.88 (4.70) −.16 (−1.25 to .94) Reference
BCS
Intervention 22.81 (6.67) 25.24 (7.13) 2.15 (.98 to 3.32) 2.84 (.79 to 4.89) .42 .007
Usual care 24.95 (6.79) 24.34 (6.21) −75 (−2.81 to 1.31) Reference
TC (mmol∙L−1)
Intervention 5.75 (1.30) 5.4 (1.09) −.23 (−.49 to .04) −.45 (−.71 to −.18) −.38 .001
Usual care 5.79 (1.04) 5.93 (.91) .22 (.05 to .38) Reference
HDL (mmol∙L−1)
Intervention 1.65 (.30) 1.62 (.33) −.02 (−.12 to 0.79) −.06 (−.15 to .04) −.19 .264
Usual care 1.59 (.34) 1.60 (.30) .04 (−.03 to .10) Reference
LDL (mmol∙L−1)
Intervention 3.44 (1.15) 3.18 (1.01) −.19 (−.42 to .04) −.30 (−.56 to −.04) −.30 .023
Usual care 3.56 (.84) 3.64 (.84) .11 (−.11 to .32) Reference
TC/HDL-C ratio (mmol∙L−1)
Intervention 3.61 (1.12) 3.47 (.93) −.09 (−.36 to .09) −.13 (−.40 to .14) −.12 .337
Usual care 3.79 (1.00) 3.83 (.90) .04 (−.19 to .26) Reference
Trig (mmol∙L−1)
Intervention 1.43 (.75) 1.31 (.58) −.08 (−.21 to .05) −.10 (−.27 to .07) −.13 .240
Usual care 1.52 (.85) 1.52 (.73) .02 (−.14 to .18) Reference
Glucose (mmol∙L−1)
Intervention 4.94 (.85) 4.81 (.52) −.14 (−.36 to .09) −.07 (−.38 to .25) −.05 .683
Usual care 5.27 (1.96) 5.32 (2.20) −.08 (−.40 to .25) Reference
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We also found further significant improvements in
leisure and vigorous PA, body mass, BMI, HRQoL
(FACT-B, TOI, FWB, and BCS) and TC and LDL-C con-
centrations in the intervention compared with usual
care. All of the significant improvements above were
found to have small effect sizes, apart from the moderate
effects observed for leisure and vigorous PA. However,
the difference in improvement in total PA for the inter-
vention group (578 MET-min∙wk−1) compared to the
usual care group was close to the recommended PA
guidelines of 600 MET-min∙wk−1, i.e. 5 × 30 min of
moderate PA). Therefore, this improvement would result
in more breast cancer survivors meeting recommended
PA guidelines, and possibly deriving associated benefits
of reduced risk of mortality and recurrence [9–12]. Of
note, more participants in the intervention group experi-
enced minimum clinically important improvements in
TOI and BCS compared with the usual care group.
However, we observed no significant improvements in
any other PA variables, body fat, and other HRQoL and
blood biomarker variables.
Our findings of increases in total, leisure-based, and
vigorous PA are consistent with previous US home-
based PA interventions with an additional PA counsel-
ling element [17, 20, 22]. All of these trials were
relatively short in duration (12 weeks) compared with
the duration of the current study (6 months). The in-
creases in PA found in the current study were encour-
aging given the larger sample size of invasive breast
cancer survivors. However, unlike two previous studies
[20, 27], we found no significant differences in self-
reported walking from baseline to post-intervention in
the intervention group compared with the usual care
group. This was possibly due to contamination in the
usual care group since these individuals were made
aware of recommended PA guidelines at baseline, as it
was thought unethical to withhold this information con-
sidering the potential health benefits associated with PA.
Table 3 Effect of PA intervention on HRQoL FACT-B and blood biomarker variables (Continued)
Insulin (pmol∙L−1)
Intervention 38.37 (34.61) 37.40 (28.64) −1.03 (15.37 to 13.31) 8.31 (−12.31 to 28.95) .20 .425
Usual care 45.45 (48.69) 37.34 (40.60) −9.84 (−29.76 to 10.08) Reference
HOMA
Intervention 1.60 (1.18) 1.78 (.88) .07 (−.62 to .76) .42 (−.88 to 1.73) .27 .520
Usual care 2.18 (1.83) 1.90 (2.09) −.41 (−2.09 to 1.26) Reference
Key: FACT-G = PWB + SWB + EWB + FWB; FACT-B = FACT-G + BCS; TOI = PWB + FWB + BCS
Baseline means (SD) are based on 80 participants except for HOMA (N = 52; intervention = 27; control = 25); Post-interventions and with-group change at follow-up
means (SD) are based on 70 participants (intervention = 37; control = 33), except HOMA (N = 38; Intervention = 20; control = 18)
Except for the blood measures (Higher scores represent better quality of life), positive ES indicate effects in favour of the exercise intervention group
Between-group effects were assessed using linear mixed model analysis including the measurements obtained at baseline and post-intervention, adjusted for the
value of the outcome variable at baseline
Table 4 Changes in performance and anthropometric measures in experimental and control groups and qualitative inferences
about the intervention effects
Variable Change in measure (%) from baseline to post-intervention
Intervention
mean (SD)
Usual care mean
(SD as a CV)
Between group
difference (90 % CI)
Effect size (d) Qualitative inference (% likelihood
of at least a small effect)
Total PA 55.9 (209.5) 17.3 (93.0) 32.9 (−9.0 to 94.0) .31 (−.10 to .72) Possibly beneficial (67)
Work-based PA −6.3 (814.8) 51.2 (327.1) −56.2 (−84.0 to 19.8) −.33 (−.73 to .07) Possibly decreases (52)
Active transport PA −24.6 (783.9) 72.3 (1452.7) −44.7 (−79.9 to 52.2) −.23 (−.63 to .16) Possibly decreases (70)
Domestic PA 81.3 (652.3) −11.4 (768.2) 104.6 (−12.5 to 378.7) .37 (−.07 to .81) Possibly beneficial (74)
Leisure PA 408.0 (1208.6) 208.9 (1615.0) 64.8 (−44.0 to 384.9) .19 (−.23 to .61) Possibly beneficial (50)
Walking PA 76.2 (851.2) 70.7 (916.4) 3.3 (−59.0 to 160.1) .02 (−.47 to .50) Possibly beneficial (51)
Moderate PA 71.1 (477.9) −18.2 (527.5) 109.1 (−.2 to 338.2) .41 (.00 to .83) Likely beneficial (80)
Vigorous PA 137.6 (2078.0) 33.6 (868.1) 77.8 (−39.2 to 420.0) .22 (−0.19 to .62) Possibly beneficial (53)
Mass −2.3 (4.7) −.1 (4.1) −2.2 (−3.9 to −.5) −.13 (−.24 to −.03) Unlikely beneficial (14)
BMI −2.3 (4.6) −.1 (4.1) −2.2 (−3.9 to −.5) −.14 (−.25 to −.03) Unlikely beneficial (18)
Body fat % 1.3 (8.0) −.1 (7.5) 1.4 (−1.6 to 4.4) .08 (−.09 to .25) Unlikely increases (11)
Key: CV = coefficient of variation
Beneficial effect reflects an increase in PA measures and a decrease in anthropometric measures
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Therefore, being part of the current study may have in-
creased the awareness of health benefits associated with
PA in the usual care group and resulted in increased
walking activity. Another possible reason for this is that
the IPAQ assesses walking in occupational and active
transport domains as well as leisure domains, in which
usual care participants engaged in more than the inter-
vention participants. Similarly, a greater amount of oc-
cupational and active transport may also explain the
non-significant between-group differences in moderate
PA, although the per-protocol analysis revealed a likely
beneficial effect of the intervention on moderate PA. It
is also important to note that, on average, the PA levels
of the intervention group were lower than that of the
usual care group at baseline, and therefore, it can be ar-
gued that they had a greater room for improvement.
However, the higher self-reported PA levels of the usual
care group was largely the result of three participants in
this group who reported much higher PA levels (≥5000
MET-min∙wk−1) compared to other participants. There-
fore, with the exception of these three participants the
levels of PA were similar in both groups, as evidenced
by the number of participants in the low and moderate
PA categories in each group (see Table 1).
Unlike similar previous studies, we found significant
reductions in body mass and BMI [17, 20, 22]. Although
the effects of the intervention compared with usual care
could be considered trivial for both outcomes, it
does represent at the least, more effective weight
management. The significant albeit small reductions in
mass and BMI were surprising given that the intervention
did not focus on weight loss and did not involve any cal-
orie restriction. However, previous research has found
positive associations between PA and healthy eating be-
haviours [44], which in turn may have had a beneficial ef-
fect on body mass and BMI. In addition, this finding could
be due in part to the longer duration of the current study
compared with the earlier studies (6 months vs. 12 weeks)
[17, 20, 22, 27]. However, we found no significant
improvements in body fat % despite the improvements in
mass and BMI. It is possible that the method of assessing
body fat %, bioelectrical impedance is not a precise
enough method to measure small changes in body fat over
time [45].
We observed significant small increases in the HRQoL
variables, FACT-B, TOI, FWB and BCS in the inter-
vention group compared to the usual care group. In
addition, a greater proportion of participants in the
intervention group achieving minimum clinical signifi-
cant improvements in BSC and TOI, which indicates
that our intervention may have specific benefits for
breast cancer survivors given that higher BCS scores
indicate fewer breast cancer-specific symptoms, such as
‘shortness of breath’, ‘change in weight’ and ‘effect of
stress on illness’, and higher TOI scores indicate both
greater physical and functional well-being and fewer
Table 5 Changes in HRQoL and blood biomarkers measures in experimental and control groups and qualitative inferences about
the intervention effects
Variable Change in measure (%) from baseline to post-intervention
Intervention
mean (SD)
Usual care mean
(SD as a CV)
Between group
difference (90 % CI)
Effect size (d) Qualitative inference (% likelihood
of at least a small effect)
Fact-B 5.9 (10.8) 2.1 (7.9) 3.7 (.0 to 7.5) .18 (.00 to .35) Possibly beneficial (59)
Fact-G 16.2 (85.1) 2.7 (8.8) 13.1 (−4.9 to 34.6) .34 (−.14 to .82) Possibly beneficial (69)
TOI 4.8 (31.1) 1.6 (10.2) 3.1 (−4.8 to 11.8) .13 (−.21 to .47) Possibly beneficial (36)
BCS 8.8 (18.5) 1.0 (28.1) 7.7 (−1.2 to 17.5) .22 (−.04 to .47) Possibly beneficial (54)
PWB 9.2 (16.2) 7.6 (14.6) 1.5 (−4.2 to 7.5) .07 (−.19 to .33) Unlikely beneficial (20)
SWB −2.5 (12.3) .7 (13.3) −3.2 (−7.8 to 1.6) −.15 (−.37 to .07) Possibly decreases (36)
EWB 5.6 (13.5) 5.6 (9.7) −.0 (−4.3 to 4.5) .00 (−0.19 to .19) Very unlikely beneficial (5)
FWB 6.2 (20.4) −1.3 (15.0) 7.6 (.6 to 15.2) .26 (.02 to .50) Possibly beneficial (66)
TC −3.5 (10.5) 3.2 (6.7) −6.5 (−9.6 to −3.3) −.41 (−.62 to −.21) Very likely beneficial (95)
HDL-C −.7 (11.0) 1.0 (6.7) −1.7 (−5.0 to 1.9) −.14 (−.42 to .15) Possibly beneficial (35)
LDL-C −4.5 (14.9) 2.5 (12.8) −6.8 (−11.6 to −1.8) −.31 (−.55 to −.08) Likely beneficial (79)
TC/LDL-C ratio −2.3 (14.5) 1.6 (11.3) −3.8 (−8.5 to 1.0) −.19 (−.43 to .05) Possibly beneficial (47)
Trig −3.5 (16.3) 1.8 (16.4) −5.2 (−10.9 to .8) −.20 (−.42 to .03) Possibly beneficial (49)
Glucose −2.9 (6.7) −6.1 (40.6) 3.4 (−6.7 to 14.5) .14 (−.30 to .59) Possibly beneficial (42)
Insulin −3.6 (87.3) −24.2 (145.4) 27.2 (−7.1 to 74.3) .31 (−.09 to .70) Possibly increases (67)
HOMA −4.5 (39.5) 0.7 (61.6) −5.2 (−26.6 to 22.5) −.12 (−.72 to .47) Possibly beneficial (41)
Key: CV = coefficient of variation
Beneficial effect reflects an increase in HRQoL measures and a decrease in blood biomarkers
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breast cancer-specific symptoms. A methodologically
similar study reported significantly greater improve-
ments for social well-being in the intervention group
versus usual care group, but no significant improve-
ments were found in the other HRQoL variables [17].
Significant improvements in the FACT-B variable in the
intervention group versus usual care group was reported
by an earlier home-based PA trial involving breast
cancer survivors, which did not have a counselling com-
ponent [26]. The reasons for the differences between
previous studies are unclear. However, it is likely that
the breast cancer stage, treatment received and both the
time since diagnosis and the end of treatment may influ-
ence participant’s responses to the items with the FACT
questionnaire.
Our findings of significant but small reductions in TC
and LDL-C were encouraging given that the existing
literature investigating the prevention of cardiovascular
disease (CVD) emphasizes the role of TC and LDL-C
with a supplementary role for HDL-C and a modest
role for TG [46–48]. Evidence supports our finding that
increased PA can favourably influence lipid profiles
[49–51]. The effect of aerobic exercise on glucose-
insulin dynamics is unclear due to a lack of agreement
between available studies [52–55]. We may not have
found reductions in glucose, insulin, and IR because of
an insufficient sample size to detect differences be-
tween groups as the trial was not powered to detect
changes in these outcomes, an insufficient reduction in
body fat [55], and/or the fact that the majority of par-
ticipants did not have diabetes [56].
The strengths of the current study include its rando-
mised design, the independent randomisation, a prag-
matic intervention and the intention-to-treat approach.
We also recruited participants over two full calendar
years; therefore, it is unlikely that our results were influ-
enced by the seasonal changes in PA suspected in previ-
ous research [26]. The limitations of this study include
lack of controlling for increased risk of type I errors
when making multiple comparisons. Moreover, self-
report measures, such as IPAQ, require participants to
recall past activity, are a subjective means of estimating
individual PA levels and are reliant on the individuals’
ability to remember levels of exposure [57]. Outcomes
were assessed by a fully trained exercise scientist, who
followed an objective, standardized assessment protocol.
However, the scientist was not blinded to group alloca-
tion which may have introduced measurement bias. In
addition, there was evidence of some contamination in
the usual care group. Six of the usual care group in-
creased their PA levels enough to move to a higher PA
category from baseline to post-intervention. This con-
tamination may have been because we informed partici-
pants in the usual care of the current recommended PA
guidelines and we did not discourage them from en-
gaging in PA. We did not control for possible changes in
the dietary habits of participants, and it is possible that
participants in the intervention group may have also
changed to healthier eating behaviours when becoming
more physically activity.
Conclusions
Within the context of these limitations, we found that a
home-based PA intervention resulted in significant but
small to moderate favourable effects on self-reported
PA, body mass, BMI, HRQoL, TC and LDL-C. The re-
sults of the trial were promising given that the interven-
tion was relatively brief, pragmatic and highly feasible
given that it was home-based and consisted of a single
in-person counselling session followed by three support
telephone calls. The portability and feasibility of the
current intervention means it could be implemented
within the NHS framework of breast cancer treatment
and follow-up both in the primary and secondary care
settings. This has the potential to capture the maximum
number of breast cancer survivors can benefit with
minimal burden to staff.
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